Ixabepilone

Ixabepilone

File:Ixabepilone.svg
Clinical data
Synonyms	Azaepothilone B
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Intravenous infusion
ATC code	L01DC04 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	N/A
Protein binding	67 to 77%
Metabolism	Extensive, hepatic, CYP3A4-mediated
Elimination half-life	52 hours
Excretion	Fecal (mostly) and renal
Identifiers
IUPAC name (1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-1,5,7, 9,9-pentamethyl-14-[(E)-1-(2-methyl-1,3-thiazol- 4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14.1.0] heptadecane-8,12-dione
CAS Number	219989-84-1
PubChem CID	6445540
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C27H42N2O5S
Molar mass	506.698 g/mol
3D model (JSmol)	Interactive image
SMILES C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](NC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C

WikiDoc Resources for Ixabepilone
Articles
Most recent articles on Ixabepilone Most cited articles on Ixabepilone Review articles on Ixabepilone Articles on Ixabepilone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ixabepilone Images of Ixabepilone Photos of Ixabepilone Podcasts & MP3s on Ixabepilone Videos on Ixabepilone
Evidence Based Medicine
Cochrane Collaboration on Ixabepilone Bandolier on Ixabepilone TRIP on Ixabepilone
Clinical Trials
Ongoing Trials on Ixabepilone at Clinical Trials.gov Trial results on Ixabepilone Clinical Trials on Ixabepilone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ixabepilone NICE Guidance on Ixabepilone NHS PRODIGY Guidance FDA on Ixabepilone CDC on Ixabepilone
Books
Books on Ixabepilone
News
Ixabepilone in the news Be alerted to news on Ixabepilone News trends on Ixabepilone
Commentary
Blogs on Ixabepilone
Definitions
Definitions of Ixabepilone
Patient Resources / Community
Patient resources on Ixabepilone Discussion groups on Ixabepilone Patient Handouts on Ixabepilone Directions to Hospitals Treating Ixabepilone Risk calculators and risk factors for Ixabepilone
Healthcare Provider Resources
Symptoms of Ixabepilone Causes & Risk Factors for Ixabepilone Diagnostic studies for Ixabepilone Treatment of Ixabepilone
Continuing Medical Education (CME)
CME Programs on Ixabepilone
International
Ixabepilone en Espanol Ixabepilone en Francais
Business
Ixabepilone in the Marketplace Patents on Ixabepilone
Experimental / Informatics
List of terms related to Ixabepilone

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.

On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. ([2]). Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra.